Frontiers in T1D Cure Call for Consolidated Researchers

The Frontiers in T1D Cure 2026 call, launched by Fundación DiabetesCERO, provides two research grants of €100,000 each to support innovative biomedical research aimed at finding a cure for type 1 diabetes (T1D). The programme funds preclinical and translational research led by experienced researchers at eligible non-profit institutions across the European Community.

Frontiers in T1D Cure 2026 Overview

The Frontiers in T1D Cure 2026 is an international biomedical research funding programme established by Fundación DiabetesCERO to accelerate scientific progress toward curing type 1 diabetes (T1D). The initiative supports high-quality research projects that combine scientific innovation with a strong translational approach, helping move promising discoveries from laboratory research toward clinical, hospital, or healthcare applications.

The programme focuses exclusively on original biomedical research aimed at curing type 1 diabetes. By investing in experienced researchers and innovative scientific ideas, the call seeks to accelerate the development of effective therapeutic solutions while strengthening scientific excellence and encouraging collaboration across the European research community.

Grant Objectives

The programme aims to:

Advance research toward a cure for type 1 diabetes.
Support innovative biomedical research.
Promote preclinical and translational research.
Accelerate the transfer of research discoveries into clinical practice.
Encourage scientific excellence and innovation.
Strengthen research talent in type 1 diabetes.
Support projects with strong therapeutic potential.
Foster collaboration between research institutions.

Priority Research Areas

Projects should focus on one or more of the following areas:

Preclinical research
Translational research
Type 1 diabetes cure research
Biomedical research
Translation of laboratory discoveries into clinical applications
Scientific innovation
Therapeutic development for type 1 diabetes

Why This Funding Matters

Type 1 diabetes remains a lifelong autoimmune disease with no definitive cure. Although treatments continue to improve, research focused on restoring insulin production or preventing immune-mediated destruction of pancreatic beta cells is essential.

The Frontiers in T1D Cure programme helps bridge the gap between laboratory discoveries and real-world clinical applications by supporting translational research that has the potential to improve future patient care.

By funding innovative research projects, the programme contributes to:

Accelerating scientific breakthroughs.
Developing potential curative therapies.
Strengthening Europe’s diabetes research ecosystem.
Supporting experienced biomedical researchers.
Promoting innovation with real clinical impact.

Funding Available

The programme provides:

Number of grants: 2
Grant value: €100,000 per project
Project duration: 24 months
Funding schedule: €50,000 per year over two years

Funding is provided exclusively for research activities.

The grant does not cover:

Indirect or overhead costs
Travel expenses
Conference participation
Non-research-related activities

Who Is Eligible?

Applications are open to researchers who meet the following requirements:

Hold a PhD.
Have an established scientific research career.
Lead an original biomedical research project focused on curing type 1 diabetes.
Be affiliated with an eligible non-profit research institution located within the European Community.

Eligible host institutions include:

Universities
Public research institutes
Private non-profit research centres
Hospitals
Other eligible non-profit biomedical research organisations

Eligible Research Projects

Projects must:

Focus on curing type 1 diabetes.
Be original biomedical research.
Demonstrate scientific innovation.
Include a translational research approach.
Show potential for future clinical application.
Be conducted by eligible research institutions.

Projects should clearly demonstrate how the proposed research could contribute to advancing curative therapies for type 1 diabetes.

Ineligible Projects

The programme does not support projects involving:

Development of medical technologies
Insulin development
Diagnostic methods
Clinical studies
Educational activities
Non-biomedical research
Projects outside the scope of curing type 1 diabetes

Applicants should ensure that their proposals align fully with the programme’s research priorities.

How to Apply

Step 1: Confirm Eligibility

Before preparing your proposal, verify that:

You hold a PhD.
You have established scientific experience.
Your institution is an eligible non-profit organisation within the European Community.
Your research focuses on curing type 1 diabetes.

Step 2: Develop Your Research Proposal

Prepare a detailed proposal explaining:

Research objectives.
Scientific background.
Research methodology.
Innovation.
Translational potential.
Expected scientific impact.
Potential clinical applications.

Clearly demonstrate how your research contributes to finding a cure for type 1 diabetes.

Step 3: Prepare Supporting Documentation

Gather all required documents, including:

Institutional information.
Principal investigator details.
Research budget.
Project timeline.
Supporting scientific documentation required by the call.

Ensure all information is complete and accurate.

Step 4: Submit Your Application

Submit the complete proposal according to the official application procedures before the published deadline.

Before submission, confirm that:

All application sections are complete.
Supporting documents are attached.
The proposal meets all eligibility requirements.
The research clearly aligns with programme objectives.

Common Mistakes to Avoid

Applicants should avoid:

Proposing clinical studies instead of translational research.
Submitting projects unrelated to curing type 1 diabetes.
Including ineligible costs such as travel or conferences.
Providing incomplete research plans.
Failing to demonstrate translational potential.
Missing required supporting documentation.
Submitting applications after the deadline.

Tips for a Strong Application

To improve your proposal:

Focus on innovative scientific approaches.
Clearly explain the translational pathway.
Demonstrate strong scientific methodology.
Highlight the potential clinical impact.
Present realistic research objectives.
Show the originality of your project.
Ensure the proposal directly supports the goal of curing type 1 diabetes.

Frequently Asked Questions (FAQs)

What is the Frontiers in T1D Cure 2026 programme?

It is an international research funding programme launched by Fundación DiabetesCERO to support innovative biomedical research aimed at finding a cure for type 1 diabetes.

How much funding is available?

Two research grants of €100,000 each will be awarded.

Who can apply?

Researchers holding a PhD with established scientific experience and affiliated with eligible non-profit research institutions in the European Community may apply.

How long can funded projects last?

Projects may run for 24 months, with funding distributed over two annual payments.

What research topics are eligible?

Eligible proposals must focus on preclinical or translational biomedical research aimed at curing type 1 diabetes.

What costs are not covered?

The programme does not fund indirect costs, travel expenses, conference participation, or projects involving medical technologies, insulin development, diagnostic methods, clinical studies, or educational activities.

What institutions are eligible to host projects?

Eligible institutions include universities, hospitals, and public or private non-profit research centres located within the European Community.

Conclusion

The Frontiers in T1D Cure 2026 programme represents an important opportunity for experienced biomedical researchers working toward a cure for type 1 diabetes. By providing €100,000 grants for innovative preclinical and translational research, Fundación DiabetesCERO aims to accelerate scientific discoveries with the potential to transform future treatment and ultimately achieve a cure for this lifelong disease.